NewsBenzingaReported Saturday, Genmab Reports Rina-S Showed 45.9% ORR, 9.5-Month mPFS And 12.1-Month mDOR In Platinum-Resistant Ovarian Cancer, With Activity Regardless Of FRα Expression Levels Reported Saturday, Genmab Reports Rina-S Showed 45.9% ORR, 9.5-Month mPFS And 12.1-Month mDOR In Platinum-Resistant Ovarian Cancer, With Activity Regardless Of FRα Expression Levels Benzinga 2026.10.05 06:56 (GMT+0) Open on Benzinga Other news The Biggest Winners from the Anthropic IPO Could Be Everyday SPY Investors Bitdeer (BTDR) Stock Falls 15.21% Intraday, Now at $2.89 Bausch + Lomb Corporation (BLCO) Discusses Phase II Results for BL1332 in Ocular Surface Pain Transcript Wells Fargo Maintains Overweight on California Resources, Raises Price Target to $77 B. Riley Securities Reiterates Buy on Orchestra BioMed Hldgs, Raises Price Target to $12 PerpetualCow: $13 Million XMR Theft Traced to Compromise of Hosting Provider 1984
Bausch + Lomb Corporation (BLCO) Discusses Phase II Results for BL1332 in Ocular Surface Pain Transcript